Archive

Neovasc announces closing of $5 million public offering of common shares

NASDAQ, TSX: NVCN VANCOUVER, Feb. 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares")...

Read More

Neovasc Announces Pricing of $5 Million Public Offering of Common Shares

NASDAQ, TSX: NVCN VANCOUVER, Feb. 26, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a...

Read More

Neovasc Announces Proposed Public Offering of Common Shares

NASDAQ, TSX: NVCN VANCOUVER, Feb. 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has commenced a proposed underwritten public offering (the "Offering") of common shares of the Company (the "Common Shares"). H.C. Wainwright...

Read More

Neovasc Provides Corporate Update

NASDAQ, TSX: NVCN VANCOUVER, Feb. 20, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina

NASDAQ, TSX: NVCN           Second U.S. patient successfully undergoes Reducer procedure under compassionate use VANCOUVER, Feb. 11, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally...

Read More